Skip to main content

Peer Review reports

From: Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study

Original Submission
27 May 2021 Submitted Original manuscript
2 Jun 2021 Reviewed Reviewer Report
5 Jun 2021 Reviewed Reviewer Report
14 Jun 2021 Reviewed Reviewer Report
9 Jul 2021 Author responded Author comments - Yongchang Zhang
Resubmission - Version 2
9 Jul 2021 Submitted Manuscript version 2
20 Jul 2021 Reviewed Reviewer Report
27 Jul 2021 Reviewed Reviewer Report
31 Jul 2021 Author responded Author comments - Yongchang Zhang
Resubmission - Version 3
31 Jul 2021 Submitted Manuscript version 3
Publishing
2 Aug 2021 Editorially accepted
13 Sep 2021 Article published 10.1186/s12916-021-02082-6

You can find further information about peer review here.

Back to article page